» Articles » PMID: 20014213

Myocardial Stunning Following Combined Modality Combretastatin-based Chemotherapy: Two Case Reports and Review of the Literature

Overview
Journal Clin Cardiol
Date 2009 Dec 17
PMID 20014213
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial stunning, known as stress cardiomyopathy, broken-heart syndrome, transient left ventricular apical ballooning, and Takotsubo cardiomyopathy, has been reported after many extracardiac stressors, but not following chemotherapy. We report 2 cases with characteristic electrocardiographic and echocardiographic features following combined modality therapy with combretastatin, a vascular-disrupting agent being studied for treatment of anaplastic thyroid cancer. In 1 patient, an ECG performed per protocol 18 hours after drug initiation showed deep, symmetric T-wave inversions in limb leads I and aVL and precordial leads V(2) through V(6). Echocardiography showed mildly reduced overall left ventricular systolic function with akinesis of the entire apex. The patient had mild elevations of troponin I. Coronary angiography revealed no epicardial coronary artery disease. The electrocardiographic and echocardiographic abnormalities resolved after several weeks. The patient remains stable from a cardiovascular standpoint and has not had a recurrence during follow-up. An electrocardiogram performed per protocol in a second patient showed deep, symmetric T-wave inversions throughout the precordial leads and a prolonged QT interval. Echocardiography showed mildly reduced left ventricular function with hypokinesis of the apical-septal wall. Acute coronary syndrome was ruled out, and both the electrocardiographic and echocardiographic changes resolved at follow-up. Although the patient remained pain-free without recurrence of anginal symptoms during long-term follow-up, the patient developed progressive malignancy and died.

Citing Articles

Pharmacological Triggers of Takotsubo Cardiomyopathy: An Updated Review of Evidence and Recommendations.

Arunkumar S, Jegaverrapandi K Curr Cardiol Rev. 2024; 20(2):50-60.

PMID: 38367261 PMC: 11107468. DOI: 10.2174/011573403X273613240125072754.


Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography.

Mampaey G, Hellemans A, de Rooster H, Schipper T, Abma E, Broeckx B Animals (Basel). 2022; 12(21).

PMID: 36359129 PMC: 9658292. DOI: 10.3390/ani12213005.


Takotsubo Syndrome: Optimizing Care with a Multidisciplinary Approach.

Kinno R, Ono K J Multidiscip Healthc. 2021; 14:2487-2499.

PMID: 34531661 PMC: 8439972. DOI: 10.2147/JMDH.S283667.


Takotsubo cardiomyopathy in cancer patients.

Desai A, Noor A, Joshi S, Kim A Cardiooncology. 2020; 5:7.

PMID: 32154014 PMC: 7048040. DOI: 10.1186/s40959-019-0042-9.


Association between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takostubo's cardiomyopathy.

Giza D, Moudgil R, Lopez-Mattei J, Kim P, Iliescu C Eur Heart J Case Rep. 2019; 1(2):ytx006.

PMID: 31020065 PMC: 6177044. DOI: 10.1093/ehjcr/ytx006.


References
1.
Grosios K, Loadman P, Swaine D, Pettit G, Bibby M . Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 2000; 20(1A):229-33. View

2.
Anderson H, Yap J, Miller M, Robbins A, Jones T, Price P . Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol. 2003; 21(15):2823-30. DOI: 10.1200/JCO.2003.05.186. View

3.
Mayer S, Lin J, Homma S, Solomon R, Lennihan L, Sherman D . Myocardial injury and left ventricular performance after subarachnoid hemorrhage. Stroke. 1999; 30(4):780-6. DOI: 10.1161/01.str.30.4.780. View

4.
Robert J . Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol. 2006; 23(1):27-37. DOI: 10.1007/s10565-006-0142-9. View

5.
Murata R, Siemann D, Overgaard J, Horsman M . Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol. 2001; 60(2):155-61. DOI: 10.1016/s0167-8140(01)00384-x. View